A Phase III Randomized Trial of Dose Escalated Radiation in Locally Advanced Pancreas Cancer (LAPC) Patients (LAP100)
Categories (click each to see list of all clinical trials associated with that category): GI (ONC), Pancreatic Cancer Center of Excellence - PCCE (ONC), Radiation Oncology (RADONC)
Current Status: Open
Phase: III (Cancer Control)
Principal Investigator: Lin, Chi
Contact Information:
Mahdi Hassan
mhassan@unmc.edu
Eligibility: https://clinicaltrials.gov/study/NCT06958328?term=NCT06958328&rank=1#participation-criteria
Summary
PRIMARY OBJECTIVE:
I. To evaluate whether dose-escalated radiation therapy (RT) improves 3-year overall survival (OS) compared to standard treatments without dose-escalated RT, in locally advanced pancreatic cancer patients without radiographic progression and with biochemical response after an initial interval of chemotherapy.
SECONDARY OBJECTIVES:
I. To evaluate and compare local progression between the two treatment arms.
II. To evaluate and compare progression-free survival (PFS) between the two treatment arms.
III. To evaluate and compare chemotherapy-free interval between the two treatment arms.
IV. To evaluate and compare toxicity within and between the two treatment arms.